X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9425) 9425
Newsletter (849) 849
Newspaper Article (648) 648
Book Chapter (43) 43
Magazine Article (20) 20
Book / eBook (16) 16
Publication (2) 2
Conference Proceeding (1) 1
Reference (1) 1
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7941) 7941
thyroid cancer (4100) 4100
female (4096) 4096
cancer (3415) 3415
male (3382) 3382
oncology (2848) 2848
middle aged (2785) 2785
thyroid neoplasms - drug therapy (2429) 2429
adult (2423) 2423
research (2085) 2085
aged (2004) 2004
thyroid neoplasms - pathology (1980) 1980
endocrinology & metabolism (1670) 1670
care and treatment (1591) 1591
animals (1470) 1470
carcinoma (1469) 1469
tumors (1438) 1438
thyroid gland (1223) 1223
cell line, tumor (1141) 1141
metastasis (1140) 1140
thyroid (1053) 1053
thyroid neoplasms - surgery (1027) 1027
oncology, experimental (970) 970
surgery (964) 964
health aspects (952) 952
thyroid neoplasms - metabolism (902) 902
drug therapy (879) 879
treatment outcome (874) 874
apoptosis (864) 864
antineoplastic agents - therapeutic use (845) 845
expression (832) 832
thyroid neoplasms - genetics (815) 815
prognosis (814) 814
thyroidectomy (800) 800
chemotherapy (792) 792
mutation (766) 766
therapy (759) 759
medicine & public health (754) 754
adolescent (750) 750
thyroid neoplasms - radiotherapy (740) 740
diagnosis (732) 732
mice (728) 728
cancer therapies (725) 725
iodine radioisotopes - therapeutic use (708) 708
thyroid diseases (705) 705
analysis (693) 693
risk factors (666) 666
patients (661) 661
genetic aspects (654) 654
thyroid neoplasms - therapy (638) 638
thyroid neoplasms - diagnosis (633) 633
aged, 80 and over (626) 626
kinases (613) 613
proteins (606) 606
retrospective studies (567) 567
hypothyroidism (564) 564
gene expression (550) 550
medicine (524) 524
antineoplastic agents - pharmacology (516) 516
child (508) 508
abridged index medicus (490) 490
development and progression (468) 468
management (468) 468
endocrinology (463) 463
thyroxine - therapeutic use (457) 457
follow-up studies (455) 455
radiotherapy (454) 454
cell proliferation - drug effects (453) 453
medical prognosis (441) 441
apoptosis - drug effects (435) 435
breast cancer (428) 428
combined modality therapy (425) 425
studies (417) 417
pathology (413) 413
young adult (406) 406
immunohistochemistry (403) 403
thyrotropin - blood (398) 398
carcinoma - drug therapy (397) 397
cell biology (397) 397
breast-cancer (384) 384
growth (380) 380
research article (377) 377
neoplasm metastasis (376) 376
medicine, general & internal (374) 374
thyroid neoplasms - diagnostic imaging (371) 371
radiology, nuclear medicine & medical imaging (369) 369
risk (368) 368
medical research (367) 367
pharmacology & pharmacy (367) 367
endocrine system diseases (366) 366
physical fitness (362) 362
survival (362) 362
mice, nude (360) 360
antineoplastic combined chemotherapy protocols - therapeutic use (359) 359
drugs (359) 359
disease (355) 355
thyroid neoplasms - complications (348) 348
iodine (347) 347
protein kinase inhibitors - therapeutic use (347) 347
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10484) 10484
German (171) 171
French (133) 133
Japanese (124) 124
Spanish (65) 65
Russian (51) 51
Italian (46) 46
Polish (43) 43
Portuguese (24) 24
Chinese (16) 16
Dutch (7) 7
Czech (6) 6
Hungarian (6) 6
Danish (4) 4
Turkish (4) 4
Croatian (3) 3
Korean (3) 3
Norwegian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Finnish (1) 1
Greek (1) 1
Hebrew (1) 1
Serbian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 8, pp. 1869 - 1876
Journal Article
Veterinary & comparative oncology, ISSN 1476-5810, 2012, Volume 10, Issue 3, pp. 194 - 205
Journal Article
European journal of endocrinology, ISSN 0804-4643, 2014, Volume 170, Issue 4, pp. 575 - 582
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 110 - 117
...) and MMTC patients in 1st line anti-angiogenic therapy with sunitinib at 50 mg/d, 4/6w. Objective response rate was the primary end-point... 
Hematology, Oncology and Palliative Medicine | Sunitinib | Phase II | Thyroid carcinoma | DIAGNOSIS | ANGIOGENESIS | GUIDELINES | INDICATOR | FOLLOW-UP | CANCER | TUMORS | TRIAL | ONCOLOGY | PAPILLARY | EXPRESSION | Lung Neoplasms - drug therapy | Lymph Nodes - pathology | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Lung Neoplasms - secondary | Adenocarcinoma, Follicular - secondary | Adenocarcinoma, Follicular - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Bone Neoplasms - drug therapy | Neck | Carcinoma - pathology | Liver Neoplasms - secondary | Pyrroles - therapeutic use | Carcinoma - secondary | Carcinoma - drug therapy | Thyroid Carcinoma, Anaplastic - drug therapy | Thyroid Carcinoma, Anaplastic - secondary | Carcinoma, Neuroendocrine - drug therapy | Liver Neoplasms - drug therapy | Treatment Outcome | Carcinoma, Neuroendocrine - secondary | Lymphatic Metastasis | Thyroid Neoplasms - drug therapy | Carcinoma, Neuroendocrine - pathology | Carcinoma, Papillary | Thyroid Carcinoma, Anaplastic - pathology | Thyroid Neoplasms - secondary | Indoles - therapeutic use | Aged | Thyroid Neoplasms - pathology | Antimitotic agents | Medical research | Care and treatment | Thyroid cancer | Endothelial growth factors | Medicine, Experimental | Metastasis | Antineoplastic agents | Endothelium | Index Medicus
Journal Article
Minerva endocrinologica, ISSN 0391-1977, 12/2012, Volume 37, Issue 4, pp. 335 - 356
.... In the last decade several novel targeted therapies have shown encouraging results and have brought hope to patients with advanced disease... 
Carcinoma, papillary | Thyroid neoplasms | Protein-tyrosine kinases | Drug therapy | SOLID TUMORS | BONE METASTASES | KINASE INHIBITOR | BREAST-CANCER | PHASE-II TRIAL | ENDOCRINOLOGY & METABOLISM | BRAIN METASTASES | DOUBLE-BLIND | EXTERNAL-BEAM RADIATION | DISTANT METASTASES | ENDOTHELIAL GROWTH-FACTOR | Doxorubicin - therapeutic use | Lung Neoplasms - drug therapy | Carcinoma, Papillary - genetics | Adenocarcinoma, Follicular - radiotherapy | Humans | Radiation Tolerance | Bone Neoplasms - secondary | Lung Neoplasms - radiotherapy | Antineoplastic Agents - therapeutic use | Thyrotropin - administration & dosage | Brain Neoplasms - surgery | Carcinoma, Papillary - secondary | Diagnostic Imaging - methods | Brain Neoplasms - secondary | Iodine Radioisotopes - therapeutic use | Lung Neoplasms - secondary | Adenocarcinoma, Follicular - secondary | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Angiogenesis Inhibitors - therapeutic use | Thyrotropin - therapeutic use | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Adenocarcinoma, Follicular - surgery | Adenoma, Oxyphilic - radiotherapy | Thyroid Neoplasms - surgery | Adenoma, Oxyphilic - surgery | Carcinoma, Papillary - drug therapy | Liver Neoplasms - surgery | Combined Modality Therapy | Thyroid Neoplasms - radiotherapy | Carcinoma, Papillary - surgery | Forecasting | Thyroidectomy | Disease Progression | Adenoma, Oxyphilic - secondary | Thyroid Neoplasms - genetics | Bone Neoplasms - radiotherapy | Algorithms | Carcinoma, Papillary - radiotherapy | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Lung Neoplasms - surgery | Radiopharmaceuticals - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
PloS one, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e85527
Somatostatin receptors (ssts) are expressed in thyroid cancer cells, but their biological significance is not well understood. The aim of this study was to... 
ANALOGS | RATIONALE | MULTIDISCIPLINARY SCIENCES | SCINTIGRAPHY | GROWTH | MEDICAL-TREATMENT | GENE-EXPRESSION | SUBTYPE EXPRESSION | PROLIFERATION | THERAPIES | CARCINOMA | Lung Neoplasms - drug therapy | Head and Neck Neoplasms - secondary | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - pathology | Receptors, Somatostatin - genetics | Neoplasm Grading | Lung Neoplasms - secondary | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Thyroid Gland - drug effects | Lung Neoplasms - genetics | Gene Expression | RNA, Messenger - genetics | Head and Neck Neoplasms - drug therapy | Octreotide - therapeutic use | Thyroid Neoplasms - genetics | Thyroid Neoplasms - drug therapy | Thyroid Gland - pathology | Head and Neck Neoplasms - genetics | Neoplasm Recurrence, Local - genetics | Aged | Thyroid Gland - metabolism | Protein Isoforms - genetics | Thyroid Neoplasms - pathology | Thyroid gland | Thyroid cancer | Metastasis | RNA | Science | Octreotide | Biology | mRNA | Scintigraphy | Kinases | Cancer therapies | Metastases | Thyroid carcinoma | Receptors | Cell growth | Immunology | Surgery | Cell cycle | Physiology | Neck | Somatostatin | Lesions | Thyroid | Nutrition | Breast cancer | Gene expression | Patients | Medicine | Hospitals | Lungs | Medical prognosis | Endocrinology | Somatostatin receptors | Cancer | Tumors
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 3, p. e60317
.... On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs... 
SUPPRESSOR | ONCOGENESIS | RNA | MULTIDISCIPLINARY SCIENCES | CERVICAL-CANCER | INTERFERENCE | MICRORNAS | NF-KAPPA-B | FACTOR RECEPTOR | EXPRESSION | CONTRIBUTES | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | MicroRNAs - metabolism | NF-kappa B - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Lung - metabolism | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | ErbB Receptors - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung - drug effects | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | MicroRNAs - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Apoptosis | Cell Movement | MicroRNA | Growth | Monoclonal antibodies | Lung cancer, Small cell | Development and progression | Lung cancer, Non-small cell | Health aspects | Cell proliferation | Laboratories | Lung cancer | Oncology | Drug delivery | Kinases | Paraffin | Cancer therapies | Metastases | Signal transduction | Cell growth | miRNA | Inhibition | Gefitinib | Sensitizing | NF-κB protein | Phenotypes | Cytokines | Epidermal growth factor receptors | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Ribonucleic acid--RNA | Patients | Pathology | Signaling | Chemotherapy | Thyroid cancer | MicroRNAs | Medical prognosis | Pancreatic cancer | Biomarkers | Mutation | Cell migration | Cervical cancer | Tumors | Cancer | Ribonucleic acid
Journal Article